Is CDNA a Buy or a Sell? The Bull and Bear Case (2026)

Last updated July 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for CareDx builds and sells diagnostics (CDNA) rests on Testing-volume growth: Testing services are the engine, with volume rising about 17% in Q1 2026 and full-year test volume guided to roughly 224,000 to 229,000. The bear case rests on reimbursement is the central risk: bears flag potential headwinds of roughly $15 million to $30 million a year from possible coverage or coding changes, which would matter against a revenue base near $413 million. Analysts covering it publish targets from $21.00 to $50.00 against a $35.80 price, so even the professionals disagree by 82% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

CareDx builds and sells diagnostics, digital tools, and services for the organ-transplant community. Its core products are AlloSure, a next-generation-sequencing test that measures donor-derived cell-free DNA (dd-cfDNA) to detect kidney and heart transplant injury, and AlloMap, a long-established gene-expression test used by the large majority of U.S. heart-transplant centers. Around these tests the company layers patient-management software, pharmacy services, and a research-and-products franchise, positioning itself as an integrated transplant platform rather than a single-test lab. The investment picture is one of a small-cap growth-plus-turnaround story. Revenue reaccelerated sharply in early 2026 (Q1 up about 39% year over year) and the company posted a rare quarterly profit, while raising full-year guidance and reshaping its portfolio through the Naveris oncology acquisition and the divestiture of its Lab Products unit. The bull case rests on durable testing-volume growth and expanding margins; the bear case centers on reimbursement risk and heavy reliance on the AlloSure and HeartCare franchises. The result is a name with genuine momentum but a valuation that already prices in continued execution.

The bull case: what would have to be true for $50.00

The most optimistic published target on CDNA is $50.00, +39.7% from the $35.80 price as of July 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

1. Testing-volume growth

Testing services are the engine, with volume rising about 17% in Q1 2026 and full-year test volume guided to roughly 224,000 to 229,000. Continued adoption of AlloSure across kidney and heart transplant surveillance is the primary top-line driver.

2. Return to profitability

After years of losses, CareDx delivered positive net income and EPS in Q1 2026 and raised adjusted EBITDA guidance to roughly $43 million to $57 million for the year. If cost discipline holds, the shift from cash burn toward sustained profit is a meaningful re-rating catalyst.

3. Portfolio reshaping

Management is buying Naveris, an HPV-driven solid-tumor diagnostics business (about $34 million in 2025 revenue with 30% to 40% growth potential), while divesting Lab Products for roughly $170 million upfront. This tightens focus on high-value clinical testing and adds an oncology adjacency.

4. Integrated transplant platform

Beyond individual tests, CareDx bundles digital workflow tools, pharmacy services, and patient management, aiming to embed itself deeply in transplant-center operations. This platform breadth is intended to widen its moat against single-test competitors.

The bear case: what would have to be true for $21.00

The most pessimistic published target is $21.00, -41.3% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks CareDx builds and sells diagnostics is worth if the risks below bite instead of the drivers above.

Reimbursement is the central risk: bears flag potential headwinds of roughly $15 million to $30 million a year from possible coverage or coding changes, which would matter against a revenue base near $413 million. The business is concentrated in the AlloSure and HeartCare franchises, so pricing pressure or a coverage decision there disproportionately affects results. Competition is intensifying, notably from Natera's Prospera test plus Eurofins Transplant Genomics, Devyser, and others, and the rivalry has spilled into litigation. The company remains unprofitable on a trailing-twelve-month basis despite the recent quarterly profit, so the turnaround is early. Integration risk from the Naveris acquisition and execution risk on the Lab Products divestiture add further uncertainty.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding CDNA already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on CDNA

5 analysts cover CDNA, with an average target of $35.40 (-1.1% against $35.80) and a split of 3 buy, 4 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the CDNA forecast and price target page.

How is CDNA valued? (as of July 2026)

Price

$35.79

Market cap

$1.85B

Forward P/E

31.57

Price / book

5.85

Beta

2.43

52-week range

$11.26 to $40.47

Snapshot for CDNA as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.

Revenue (TTM): ~$413M
Q1 2026 revenue: ~$118M (+39% YoY)
2026 revenue guidance: ~$447M to $465M
2026 adj. EBITDA guidance: ~$43M to $57M
Net income (TTM): ~-$8M (Q1 2026 positive)
Market cap: ~$1.1B

CDNA trades at roughly 2.5 to 3 times trailing revenue, a multiple that reflects reaccelerating growth and an early return to profitability rather than deep value. A cash cushion near $200 million and positive adjusted EBITDA guidance give it flexibility, but the trailing net loss means the market is paying for future execution. Reimbursement outcomes are the swing factor for whether the current multiple proves justified.

How do you decide if CDNA is a buy?

Rather than asking whether CDNA is a buy in the abstract, it tends to help to answer four questions:

Thesis: do you believe the bull case above, and is it still true today?
Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
Overlap: check whether you already hold CDNA indirectly through an index or sector ETF before adding more.

What would change your mind on CDNA

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

Bull case breaks if: Testing-volume growth stalls in the reported numbers rather than in the narrative around them.
Bear case breaks if: reimbursement is the central risk: bears flag potential headwinds of roughly $15 million to $30 million a year from possible coverage or coding changes, which would matter against a revenue base near $413 million fails to materialise over several reporting periods while the drivers keep compounding.
Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the CDNA stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about CDNA against your real portfolio and see your actual exposure before deciding.

Investing in CareDx builds and sells diagnostics with AI

Connect the broker you already use and ask Walnut's AI how CDNA fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.

Create a free Walnut account

FAQ

Is CDNA a good stock to buy right now?

That depends on which case you find more convincing, and both are on this page. The bull case rests on Testing-volume growth, with revenue (ttm) at ~$413M. The bear case rests on reimbursement is the central risk: bears flag potential headwinds of roughly $15 million to $30 million a year from possible coverage or coding changes, which would matter against a revenue base near $413 million. Analysts covering it are spread from $21.00 to $50.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Should I sell CDNA?

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Reimbursement is the central risk: bears flag potential headwinds of roughly $15 million to $30 million a year from possible coverage or coding changes, which would matter against a revenue base near $413 million. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $21.00, -41.3% from the $35.80 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

What is the bull case for CDNA?

Testing-volume growth. Testing services are the engine, with volume rising about 17% in Q1 2026 and full-year test volume guided to roughly 224,000 to 229,000. The most optimistic analyst target on CDNA is $50.00, +39.7% from the $35.80 price. That figure is only reachable if this thesis works close to its best case.

What is the bear case for CDNA?

What does CareDx builds and sells diagnostics do?

CareDx builds and sells diagnostics, digital tools, and services for the organ-transplant community.

What would have to change for CDNA to stop being worth holding?

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Testing-volume growth) stalling in the reported numbers rather than in the narrative, the risk above (reimbursement is the central risk: bears flag potential headwinds of roughly $15 million to $30 million a year from possible coverage or coding changes, which would matter against a revenue base near $413 million) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What does CareDx (CDNA) actually do?

CareDx provides diagnostics and services for the organ-transplant community. Its flagship tests, AlloSure and AlloMap, monitor kidney and heart transplant recipients for signs of rejection, and it also sells patient-management software and pharmacy services to transplant centers.

Is CareDx profitable?

It turned a quarterly profit in Q1 2026 with positive net income and EPS, and guided to positive full-year adjusted EBITDA. However, on a trailing-twelve-month basis it was still slightly net-loss-making as of early 2026, so the profitability trend is recent and not yet fully established.

How fast is CareDx growing?

Growth reaccelerated sharply in early 2026, with Q1 revenue up about 39% year over year and testing volume up roughly 17%. Full-year 2026 revenue guidance of about $447 million to $465 million implies continued strong double-digit growth.

Walnut is informational, not investment advice, and gives no verdict on CDNA. Analyst targets referenced here come from a July 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.